SAB Biotherapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell SABS and other ETFs, options, and stocks.About SABS
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases.
CEOSamuel J. Reich
CEOSamuel J. Reich
Employees63
Employees63
HeadquartersMiami Beach, Florida
HeadquartersMiami Beach, Florida
Founded2014
Founded2014
Employees63
Employees63
SABS Key Statistics
Market cap188.05M
Market cap188.05M
Price-Earnings ratio-1.28
Price-Earnings ratio-1.28
Dividend yield—
Dividend yield—
Average volume366.98K
Average volume366.98K
High today$4.13
High today$4.13
Low today$3.91
Low today$3.91
Open price$3.99
Open price$3.99
Volume567.69K
Volume567.69K
52 Week high$6.60
52 Week high$6.60
52 Week low$1.00
52 Week low$1.00
Stock Snapshot
As of today, SAB Biotherapeutics(SABS) shares are valued at $3.97. The company's market cap stands at 188.05M, with a P/E ratio of -1.28.
On 2025-12-18, SAB Biotherapeutics(SABS) stock moved within a range of $3.91 to $4.13. With shares now at $3.97, the stock is trading +1.5% above its intraday low and -3.9% below the session's peak.
Trading activity shows a volume of 567.69K, compared to an average daily volume of 366.98K.
The stock's 52-week range extends from a low of $1.00 to a high of $6.60.
The stock's 52-week range extends from a low of $1.00 to a high of $6.60.
Analyst ratings
100%
of 6 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own SABS. This list is generated using Robinhood data, and it’s not a recommendation.